{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:02:37Z","timestamp":1794873757217,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-159531"],"award-info":[{"award-number":["PJT-159531"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MC2-157081"],"award-info":[{"award-number":["MC2-157081"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153279"],"award-info":[{"award-number":["PJT-153279"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-001076"],"award-info":[{"award-number":["MJFF-001076"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["MJFF-001076"],"award-info":[{"award-number":["MJFF-001076"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000304","name":"Parkinson\u2019s UK","doi-asserted-by":"publisher","award":["K-1405"],"award-info":[{"award-number":["K-1405"]}],"id":[{"id":"10.13039\/501100000304","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael J. Fox Foundation for Parkinson\u2019s Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Accumulation of \u03b1-synuclein into toxic oligomers or fibrils is implicated in dopaminergic neurodegeneration in Parkinson\u2019s disease. Here we performed a high-throughput, proteome-wide peptide screen to identify protein-protein interaction inhibitors that reduce \u03b1-synuclein oligomer levels and their associated cytotoxicity. We find that the most potent peptide inhibitor disrupts the direct interaction between the C-terminal region of \u03b1-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B), a component of the Endosomal Sorting Complex Required for Transport-III (ESCRT-III). We show that \u03b1-synuclein impedes endolysosomal activity via this interaction, thereby inhibiting its own degradation. Conversely, the peptide inhibitor restores endolysosomal function and thereby decreases \u03b1-synuclein levels in multiple models, including female and male human cells harboring disease-causing \u03b1-synuclein mutations. Furthermore, the peptide inhibitor protects dopaminergic neurons from \u03b1-synuclein-mediated degeneration in hermaphroditic\n                    <jats:italic>C. elegans<\/jats:italic>\n                    and preclinical Parkinson\u2019s disease models using female rats. Thus, the \u03b1-synuclein-CHMP2B interaction is a potential therapeutic target for neurodegenerative disorders.\n                  <\/jats:p>","DOI":"10.1038\/s41467-023-37464-2","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T06:03:16Z","timestamp":1681884196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Disrupting the \u03b1-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson\u2019s disease"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7791-1238","authenticated-orcid":false,"given":"Satra","family":"Nim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0766-2061","authenticated-orcid":false,"given":"Darren M.","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-4405","authenticated-orcid":false,"given":"Carles","family":"Corbi-Verge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Perez-Riba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grishma","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2057-7419","authenticated-orcid":false,"given":"Mitchell L.","family":"De Snoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie G.","family":"Ngana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-9773","authenticated-orcid":false,"given":"Jisun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M. A.","family":"El-Agnaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Rennella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2054-1915","authenticated-orcid":false,"given":"Suneil K.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9384-1305","authenticated-orcid":false,"given":"Lorraine V.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-152X","authenticated-orcid":false,"given":"Philip M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"37464_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-016-0131-4","volume":"14","author":"C Corbi-Verge","year":"2016","unstructured":"Corbi-Verge, C. & Kim, P. M. Motif mediated protein-protein interactions as drug targets. Cell Commun. Signal 14, 8 (2016).","journal-title":"Cell Commun. Signal"},{"key":"37464_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrd3680","volume":"11","author":"A Mullard","year":"2012","unstructured":"Mullard, A. Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 11, 173\u2013175 (2012).","journal-title":"Nat. Rev. Drug Discov."},{"key":"37464_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-pharmtox-010716-104805","volume":"57","author":"C Corbi-Verge","year":"2017","unstructured":"Corbi-Verge, C., Garton, M., Nim, S. & Kim, P. M. Strategies to develop inhibitors of motif-mediated protein-protein interactions as drug leads. Annu. Rev. Pharm. Toxicol. 57, 39\u201360 (2017).","journal-title":"Annu. Rev. Pharm. Toxicol."},{"key":"37464_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3690","volume":"14","author":"TL Nero","year":"2014","unstructured":"Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J. & Parker, M. W. Oncogenic protein interfaces: small molecules, big challenges. Nat. Rev. Cancer 14, 248\u2013262 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"37464_CR5","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1111\/bph.14345","volume":"175","author":"DM O\u2019Hara","year":"2018","unstructured":"O\u2019Hara, D. M., Kalia, S. K. & Kalia, L. V. Emerging disease-modifying strategies targeting \u03b1-synuclein for the treatment of Parkinson\u2019s disease. Br. J. Pharm. 175, 3080\u20133089 (2018).","journal-title":"Br. J. Pharm."},{"key":"37464_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ana.23746","volume":"73","author":"LV Kalia","year":"2013","unstructured":"Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M. & Lang, A. E. \u03b1-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73, 155\u2013169 (2013).","journal-title":"Ann. Neurol."},{"key":"37464_CR7","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"37464_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/mds.26477","volume":"31","author":"M Xilouri","year":"2016","unstructured":"Xilouri, M., Brekk, O. R. & Stefanis, L. Autophagy and alpha-synuclein: relevance to Parkinson\u2019s disease and related synucleopathies. Mov. Disord. 31, 178\u2013192 (2016).","journal-title":"Mov. Disord."},{"key":"37464_CR9","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1074\/jbc.M114.620484","volume":"290","author":"H Cheruvara","year":"2015","unstructured":"Cheruvara, H., Allen-Baume, V. L., Kad, N. M. & Mason, J. M. Intracellular screening of a peptide library to derive a potent peptide inhibitor of \u03b1-synuclein aggregation. J. Biol. Chem. 290, 7426\u20137435 (2015).","journal-title":"J. Biol. Chem."},{"key":"37464_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.molcel.2014.05.032","volume":"55","author":"P Tompa","year":"2014","unstructured":"Tompa, P., Davey, N. E., Gibson, T. J. & Babu, M. M. A million peptide motifs for the molecular biologist. Mol. Cell 55, 161\u2013169 (2014).","journal-title":"Mol. Cell"},{"key":"37464_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1873-3468.12037","volume":"590","author":"S Garrido-Urbani","year":"2016","unstructured":"Garrido-Urbani, S. et al. Proteomic peptide phage display uncovers novel interactions of the PDZ1-2 supramodule of syntenin. FEBS Lett. 590, 3\u201312 (2016).","journal-title":"FEBS Lett."},{"key":"37464_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nchembio.2026","volume":"12","author":"S Nim","year":"2016","unstructured":"Nim, S. et al. Pooled screening for antiproliferative inhibitors of protein-protein interactions. Nat. Chem. Biol. 12, 275\u2013281 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"37464_CR13","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1073\/pnas.1312296111","volume":"111","author":"Y Ivarsson","year":"2014","unstructured":"Ivarsson, Y. et al. Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes. Proc. Natl Acad. Sci. USA 111, 2542\u20132547 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37464_CR14","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1371\/journal.pone.0001867","volume":"3","author":"TF Outeiro","year":"2008","unstructured":"Outeiro, T. F. et al. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3, e1867 (2008).","journal-title":"PLoS ONE"},{"key":"37464_CR15","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1016\/j.celrep.2019.10.089","volume":"29","author":"M Kiechle","year":"2019","unstructured":"Kiechle, M. et al. In vivo protein complementation demonstrates presynaptic \u03b1-synuclein oligomerization and age-dependent accumulation of 8-16-mer oligomer species. Cell Rep. 29, 2862\u20132874 (2019).","journal-title":"Cell Rep."},{"key":"37464_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2051-5960-1-6","volume":"1","author":"H Dimant","year":"2013","unstructured":"Dimant, H. et al. Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol. Commun. 1, 6 (2013).","journal-title":"Acta Neuropathol. Commun."},{"key":"37464_CR17","doi-asserted-by":"publisher","first-page":"17962","DOI":"10.1074\/jbc.M802283200","volume":"283","author":"JE Tetzlaff","year":"2008","unstructured":"Tetzlaff, J. E. et al. CHIP targets toxic alpha-synuclein oligomers for degradation. J. Biol. Chem. 283, 17962\u201317968 (2008).","journal-title":"J. Biol. Chem."},{"key":"37464_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-021-00497-6","volume":"16","author":"KS Chen","year":"2021","unstructured":"Chen, K. S. et al. Small molecule inhibitors of \u03b1-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Mol. Neurodegener. 16, 77 (2021).","journal-title":"Mol. Neurodegener."},{"key":"37464_CR19","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/mds.27506","volume":"33","author":"M Picillo","year":"2018","unstructured":"Picillo, M. et al. Parkinsonism due to A53E \u03b1-synuclein gene mutation: clinical, genetic, epigenetic, and biochemical features. Mov. Disord. 33, 1950\u20131955 (2018).","journal-title":"Mov. Disord."},{"key":"37464_CR20","doi-asserted-by":"publisher","first-page":"e14695","DOI":"10.1371\/journal.pone.0014695","volume":"6","author":"LV Kalia","year":"2011","unstructured":"Kalia, L. V. et al. Ubiquitinylation of \u03b1-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLoS ONE 6, e14695 (2011).","journal-title":"PLoS ONE"},{"key":"37464_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nature06172","volume":"449","author":"MD Stuchell-Brereton","year":"2007","unstructured":"Stuchell-Brereton, M. D. et al. ESCRT-III recognition by VPS4 ATPases. Nature 449, 740\u2013744 (2007).","journal-title":"Nature"},{"key":"37464_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3250","volume":"4","author":"E Morel","year":"2013","unstructured":"Morel, E. et al. Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system. Nat. Commun. 4, 2250 (2013).","journal-title":"Nat. Commun."},{"key":"37464_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41580-019-0177-4","volume":"21","author":"M Vietri","year":"2020","unstructured":"Vietri, M., Radulovic, M. & Stenmark, H. The many functions of ESCRTs. Nat. Rev. Mol. Cell Biol. 21, 25\u201342 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"37464_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/ng1609","volume":"37","author":"G Skibinski","year":"2005","unstructured":"Skibinski, G. et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806\u2013808 (2005).","journal-title":"Nat. Genet."},{"key":"37464_CR25","doi-asserted-by":"publisher","first-page":"e9872","DOI":"10.1371\/journal.pone.0009872","volume":"5","author":"LE Cox","year":"2010","unstructured":"Cox, L. E. et al. Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS ONE 5, e9872 (2010).","journal-title":"PLoS ONE"},{"key":"37464_CR26","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/ng.3955","volume":"49","author":"D Chang","year":"2017","unstructured":"Chang, D. et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson\u2019s disease risk loci. Nat. Genet. 49, 1511\u20131516 (2017).","journal-title":"Nat. Genet."},{"key":"37464_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00401-015-1475-3","volume":"130","author":"EL Clayton","year":"2015","unstructured":"Clayton, E. L. et al. Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathol. 130, 511\u2013523 (2015).","journal-title":"Acta Neuropathol."},{"key":"37464_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1440-1789.2012.01346.x","volume":"33","author":"T Kurashige","year":"2013","unstructured":"Kurashige, T. et al. Localization of CHMP2B-immunoreactivity in the brainstem of Lewy body disease. Neuropathology 33, 237\u2013245 (2013).","journal-title":"Neuropathology"},{"key":"37464_CR29","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/hmg\/ddv633","volume":"25","author":"B Spencer","year":"2016","unstructured":"Spencer, B. et al. \u03b1-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum. Mol. Genet. 25, 1100\u20131115 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"37464_CR30","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/cmi.12041","volume":"15","author":"G Effantin","year":"2013","unstructured":"Effantin, G. et al. ESCRT-III CHMP2A and CHMP3 form variable helical polymers in vitro and act synergistically during HIV-1 budding. Cell Microbiol. 15, 213\u2013226 (2013).","journal-title":"Cell Microbiol."},{"key":"37464_CR31","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/hmg\/ddq100","volume":"19","author":"H Urwin","year":"2010","unstructured":"Urwin, H. et al. Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Hum. Mol. Genet. 19, 2228\u20132238 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"37464_CR32","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135\u20132146 (2014).","journal-title":"Nat. Protoc."},{"key":"37464_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nsmb.3194","volume":"23","author":"MD Tuttle","year":"2016","unstructured":"Tuttle, M. D. et al. Solid-state NMR structure of a pathogenic fibril of full-length human \u03b1-synuclein. Nat. Struct. Mol. Biol. 23, 409\u2013415 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"37464_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","volume":"35","author":"Y Chu","year":"2009","unstructured":"Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W. & Kordower, J. H. Alterations in lysosomal and proteasomal markers in Parkinson\u2019s disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385\u2013398 (2009).","journal-title":"Neurobiol. Dis."},{"key":"37464_CR35","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.yexcr.2008.09.020","volume":"315","author":"MS Pols","year":"2009","unstructured":"Pols, M. S. & Klumperman, J. Trafficking and function of the tetraspanin CD63. Exp. Cell Res. 315, 1584\u20131592 (2009).","journal-title":"Exp. Cell Res."},{"key":"37464_CR36","doi-asserted-by":"crossref","unstructured":"Guerra, F. & Bucci, C. Multiple roles of the small GTPase Rab7. Cells 5, 34 (2016).","DOI":"10.3390\/cells5030034"},{"key":"37464_CR37","doi-asserted-by":"crossref","unstructured":"Borchers A. C., Langemeyer, L. & Ungermann, C., Who\u2019s in control? Principles of Rab GTPase activation in endolysosomal membrane trafficking and beyond. J. Cell Biol. 220, e202105120 (2021).","DOI":"10.1083\/jcb.202105120"},{"key":"37464_CR38","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/hmg\/ddw185","volume":"25","author":"J Magalhaes","year":"2016","unstructured":"Magalhaes, J. et al. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum. Mol. Genet. 25, 3432\u20133445 (2016).","journal-title":"Hum. Mol. Genet"},{"key":"37464_CR39","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","volume":"27","author":"MJ Kim","year":"2018","unstructured":"Kim, M. J., Jeon, S., Burbulla, L. F. & Krainc, D. Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function. Hum. Mol. Genet. 27, 1972\u20131988 (2018).","journal-title":"Hum. Mol. Genet"},{"key":"37464_CR40","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/NEN.0b013e318211c86a","volume":"70","author":"S Higashi","year":"2011","unstructured":"Higashi, S. et al. Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 70, 264\u2013280 (2011).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"37464_CR41","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/jnc.14704","volume":"150","author":"L Stefanis","year":"2019","unstructured":"Stefanis, L. et al. How is alpha-synuclein cleared from the cell? J. Neurochem 150, 577\u2013590 (2019).","journal-title":"J. Neurochem"},{"key":"37464_CR42","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1073\/pnas.1109356108","volume":"108","author":"GK Tofaris","year":"2011","unstructured":"Tofaris, G. K. et al. Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl Acad. Sci. USA 108, 17004\u201317009 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37464_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"37464_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnins.2018.00080","volume":"12","author":"JC Bridi","year":"2018","unstructured":"Bridi, J. C. & Hirth, F. Mechanisms of \u03b1-synuclein induced synaptopathy in Parkinson\u2019s disease. Front. Neurosci. 12, 80 (2018).","journal-title":"Front. Neurosci."},{"key":"37464_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich, J. B., Kalia, L. V. & Brotchie, J. M. Animal models of \u03b1-synucleinopathy for Parkinson disease drug development. Nat. Rev. Neurosci. 18, 515\u2013529 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"37464_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1750-1326-5-43","volume":"5","author":"JB Koprich","year":"2010","unstructured":"Koprich, J. B., Johnston, T. H., Reyes, M. G., Sun, X. & Brotchie, J. M. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1\/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson\u2019s disease. Mol. Neurodegener. 5, 43 (2010).","journal-title":"Mol. Neurodegener."},{"key":"37464_CR47","doi-asserted-by":"publisher","first-page":"e17698","DOI":"10.1371\/journal.pone.0017698","volume":"6","author":"JB Koprich","year":"2011","unstructured":"Koprich, J. B. et al. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson\u2019s disease produced by decreasing doses of alpha-synuclein. PLoS ONE 6, e17698 (2011).","journal-title":"PLoS ONE"},{"key":"37464_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40478-020-0894-0","volume":"8","author":"C McKinnon","year":"2020","unstructured":"McKinnon, C. et al. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by alpha-synuclein. Acta Neuropathol. Commun. 8, 17 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"37464_CR49","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty, S. & Jenner, P. Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharm. 164, 1357\u20131391 (2011).","journal-title":"Br. J. Pharm."},{"key":"37464_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1090278","volume":"302","author":"AB Singleton","year":"2003","unstructured":"Singleton, A. B. et al. Alpha-synuclein locus triplication causes Parkinson\u2019s disease. Science 302, 841 (2003).","journal-title":"Science"},{"key":"37464_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1453","volume":"2","author":"MJ Devine","year":"2011","unstructured":"Devine, M. J. et al. Parkinson\u2019s disease induced pluripotent stem cells with triplication of the \u03b1-synuclein locus. Nat. Commun. 2, 440 (2011).","journal-title":"Nat. Commun."},{"key":"37464_CR52","doi-asserted-by":"crossref","unstructured":"Barbuti, P. et al, Using high-content screening to generate single-cell gene-corrected patient-derived iPS clones reveals excess alpha-synuclein with familial Parkinson\u2019s disease point mutation A30P. Cells 9, 2065 (2020).","DOI":"10.3390\/cells9092065"},{"key":"37464_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41591-019-0739-1","volume":"26","author":"AH Laperle","year":"2020","unstructured":"Laperle, A. H. et al. iPSC modeling of young-onset Parkinson\u2019s disease reveals a molecular signature of disease and novel therapeutic candidates. Nat. Med. 26, 289\u2013299 (2020).","journal-title":"Nat. Med."},{"key":"37464_CR54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nbd.2015.04.009","volume":"79","author":"NN Vaikath","year":"2015","unstructured":"Vaikath, N. N. et al. Generation and characterization of novel conformation-specific monoclonal antibodies for \u03b1-synuclein pathology. Neurobiol. Dis. 79, 81\u201399 (2015).","journal-title":"Neurobiol. Dis."},{"key":"37464_CR55","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/mds.26754","volume":"31","author":"NK Majbour","year":"2016","unstructured":"Majbour, N. K. et al. Longitudinal changes in CSF alpha-synuclein species reflect Parkinson\u2019s disease progression. Mov. Disord. 31, 1535\u20131542 (2016).","journal-title":"Mov. Disord."},{"key":"37464_CR56","doi-asserted-by":"publisher","first-page":"113900","DOI":"10.1016\/j.expneurol.2021.113900","volume":"347","author":"EM Szeg\u00f6","year":"2022","unstructured":"Szeg\u00f6, E. M. et al. Rab7 reduces \u03b1-synuclein toxicity in rats and primary neurons. Exp. Neurol. 347, 113900 (2022).","journal-title":"Exp. Neurol."},{"key":"37464_CR57","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1080\/15548627.2022.2045534","volume":"18","author":"S Prieto Huarcaya","year":"2022","unstructured":"Prieto Huarcaya, S. et al. Recombinant pro-CTSD (cathepsin D) enhances SNCA\/\u03b1-synuclein degradation in \u03b1-synucleinopathy models. Autophagy 18, 1127\u20131151 (2022).","journal-title":"Autophagy"},{"key":"37464_CR58","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1073\/pnas.1711837115","volume":"115","author":"M Garton","year":"2018","unstructured":"Garton, M. et al. Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB. Proc. Natl Acad. Sci. USA 115, 1505\u20131510 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"37464_CR59","doi-asserted-by":"publisher","first-page":"79401","DOI":"10.18632\/oncotarget.12708","volume":"7","author":"Y Li","year":"2016","unstructured":"Li, Y., Zheng, X., Gong, M. & Zhang, J. Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget 7, 79401\u201379407 (2016).","journal-title":"Oncotarget"},{"key":"37464_CR60","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev-neuro-111020-100834","volume":"45","author":"RC Challis","year":"2022","unstructured":"Challis, R. C. et al. Adeno-associated virus toolkit to target diverse brain cells. Annu. Rev. Neurosci. 45, 447\u2013469 (2022).","journal-title":"Annu. Rev. Neurosci."},{"key":"37464_CR61","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/brain\/awz023","volume":"142","author":"A Whone","year":"2019","unstructured":"Whone, A. et al. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson\u2019s disease. Brain 142, 512\u2013525 (2019).","journal-title":"Brain"},{"key":"37464_CR62","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1136\/jnnp-2020-322904","volume":"91","author":"RM Richardson","year":"2020","unstructured":"Richardson, R. M. et al. Data-driven evolution of neurosurgical gene therapy delivery in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 91, 1210\u20131218 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"37464_CR63","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/mds.27308","volume":"33","author":"Y Meng","year":"2018","unstructured":"Meng, Y. et al. Is there a role for MR-guided focused ultrasound in Parkinson\u2019s disease? Mov. Disord. 33, 575\u2013579 (2018).","journal-title":"Mov. Disord."},{"key":"37464_CR64","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/mds.29190","volume":"37","author":"Y Meng","year":"2022","unstructured":"Meng, Y. et al. Unilateral putaminal delivery of recombinant glucocerebrosidase using transcranial low-intensity MR-guided focused ultrasound in Parkinson\u2019s disease. Mov. Disord. 37, 2134\u20132139 (2022).","journal-title":"Mov. Disord."},{"key":"37464_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0079-6565(98)00025-9","volume":"34","author":"M Sattler","year":"1999","unstructured":"Sattler, M., Schleucher, J. & Griesinger C. Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients. Prog. Nucl. Magn. Reson. Spectrosc. 34, 93\u2013158 (1999).","journal-title":"Prog. Nucl. Magn. Reson. Spectrosc."},{"key":"37464_CR66","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/genetics\/77.1.71","volume":"77","author":"S Brenner","year":"1974","unstructured":"Brenner, S. The genetics of Caenorhabditis elegans. Genetics 77, 71\u201394 (1974).","journal-title":"Genetics"},{"key":"37464_CR67","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1074\/jbc.M504860200","volume":"281","author":"T Kuwahara","year":"2006","unstructured":"Kuwahara, T. et al. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 281, 334\u2013340 (2006).","journal-title":"J. Biol. Chem."},{"key":"37464_CR68","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1126\/science.1144874","volume":"317","author":"K Fujisawa","year":"2007","unstructured":"Fujisawa, K., Wrana, J. L. & Culotti, J. G. The slit receptor EVA-1 coactivates a SAX-3\/Robo mediated guidance signal in C. elegans. Science 317, 1934\u20131938 (2007).","journal-title":"Science"},{"key":"37464_CR69","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","volume":"39","author":"T Schallert","year":"2000","unstructured":"Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L. & Bland, S. T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39, 777\u2013787 (2000).","journal-title":"Neuropharmacology"},{"key":"37464_CR70","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41593-019-0457-5","volume":"22","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X. et al. Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat. Neurosci. 22, 1248\u20131257 (2019).","journal-title":"Nat. Neurosci."},{"key":"37464_CR71","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.neuron.2020.03.022","volume":"106","author":"A Jais","year":"2020","unstructured":"Jais, A. et al. PNOCARC neurons promote hyperphagia and obesity upon high-fat-diet feeding. Neuron 106, 1009\u20131025 (2020).","journal-title":"Neuron"},{"key":"37464_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13787-x","volume":"11","author":"Z He","year":"2020","unstructured":"He, Z. et al. Transmission of tauopathy strains is independent of their isoform composition. Nat. Commun. 11, 7 (2020).","journal-title":"Nat. Commun."},{"key":"37464_CR73","doi-asserted-by":"crossref","unstructured":"O\u2019Hara, D. M., Kapadia, M., Ping, S., Kalia, S. K. & Kalia, L. V., Semi-quantitative determination of dopaminergic neuron density in the substantia nigra of rodent models using automated image analysis. J. Vis. Exp. 168, e62062 (2021).","DOI":"10.3791\/62062-v"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37464-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T06:05:51Z","timestamp":1681884351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-37464-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37464"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-37464-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"21 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"University of Toronto has submitted a patent application covering composition and use of the peptides, as well as the screening methods (US Patent 63\/289,912, currently pending with PCT filed) with S.N., C.C.V., S.K.K., L.V.K., and P.M.K. as inventors. S.K.K., L.V.K., and P.M.K. have co-founded Synepark Therapeutics Inc to commercialize aspects of this research. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2150"}}